Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629345 | 1.00 | DCUN1D1 (0.47) | DCUN1D1LDHANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12615990 | 0.85 | ALDH1A1 (0.38) | DCUN1D1LDHAALDH1A1KMT2AIDO1 | |
| SCHEMBL1200471 | 0.85 | NOTUM (0.42) | DCUN1D1LDHACYP2D6IDO1NOTUM | |
| SCHEMBL1308125 | 0.82 | CHEK1 (0.36) | DCUN1D1LDHANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5814847 | 0.82 | KMO (0.36) | DCUN1D1LDHANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15372746 | 0.82 | IDO1 (0.45) | DCUN1D1LDHANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5815118 | 0.78 | JAK2 (0.41) | LDHACYP1A2LMNAPTGESGUSB | |
| SCHEMBL5815364 | 0.77 | ALDH1A1 (0.49) | SMN1; SMN2HPGDTP53ALDH1A1KMT2A | |
| SCHEMBL705941 | 0.77 | HSD11B1 (0.44) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL12496464 | 0.77 | ESR1 (0.39) | DCUN1D1LDHANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| EP-0312353-B1 | Zearalanol derivatives with anabolic activity | MALLINCKRODT VETERINARY INC (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0312353-A2 | Zearalanol derivatives with anabolic activity | MALLINCKRODT VETERINARY, INC. (US) | 1989-04-19 | — | — | EP | claimed |
| JP-8269023-A | — | — | None | — | — | JP | disclosed |
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | KYOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, TEIKYO UNIVERSITY and THE UNIVERSITY OF TOKYO (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2022061193-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-17 | — | — | US | disclosed |
| CN-103641820-B | Tetrazolium imines coumarins copper ion fluorescence probe and preparation method thereof | NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-103641820-A | Tetrazolium imine coumarins copper ion fluorescence probe and preparation method thereof | UNIV NANJING SCIENCE & TECH | 2014-03-19 | — | — | CN | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| JP-H08269023-A | PRODUCTION OF 5-SUBSTITUTED TETRAZOLE COMPOUND | SUMITOMO CHEM CO LTD | 1996-10-15 | — | — | JP | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996013489-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLES | NOVARTIS AG (CH) | 1996-05-09 | — | — | WO | disclosed |
| EP-0312353-B1 | Zearalanol derivatives with anabolic activity | MALLINCKRODT VETERINARY INC (US) | 1995-05-17 | — | — | EP | disclosed |
| US-4849447-A | GROWTH PROMOTERS FOR MEAT-PRODUCING ANIMALS | PITMAN-MOORE, INC. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0312353-A2 | Zearalanol derivatives with anabolic activity | MALLINCKRODT VETERINARY, INC. (US) | 1989-04-19 | — | — | EP | disclosed |
| US-4647572-A | Iodoallyl and iodopropargyl substituted tetrazoles and anti-microbial compositions thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 1987-03-03 | — | — | US | disclosed |
| EP-0107859-A1 | Tetrazole compounds, process for preparing the same and antibacterial and antifungal compositions containing the same as active ingredient | MEIJI SEIKA KAISHA LTD. (JP) | 1984-05-09 | — | — | EP | disclosed |
| US-4388463-A | 6-Keto-morphinan analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1983-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | VDR, CYP24A1, CYP2R1 | DCUN1D1 2933/4885LDHA 3694/4885NPC1 206/4885 |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | DCUN1D1 2933/4885LDHA 3694/4885NPC1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.